CA2291889A1 - Methodology for predicting and/or diagnosing disease - Google Patents
Methodology for predicting and/or diagnosing disease Download PDFInfo
- Publication number
- CA2291889A1 CA2291889A1 CA002291889A CA2291889A CA2291889A1 CA 2291889 A1 CA2291889 A1 CA 2291889A1 CA 002291889 A CA002291889 A CA 002291889A CA 2291889 A CA2291889 A CA 2291889A CA 2291889 A1 CA2291889 A1 CA 2291889A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- disorder
- conducted
- comparison
- samples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
Abstract
Disorders are diagnosed by analyzing biological samples of ad libitum-fed and dietary-restricted individuals to generate frequency distribution patterns representative of molecular constituents of the samples, and comparing the patterns.
Description
WO 99/50437 PC'T/US99106762
Claims (19)
1. In a method for diagnosing and/or predicting disorders in which biological samples are analyzed to generate frequency distribution patterns representative of molecular constituents of said samples, the improvement which comprises comparing frequency distribution patterns of constituents of samples of ad libitum-fed and dietary-restricted individuals.
2. A method according to claim 1, wherein said samples comprise body fluids.
3. A method according to claim 2, wherein said body fluids are selected from the group consisting of serum, plasma, platelets, saliva and urine.
4. A method according to claim 1, wherein said disorder is selected from the group consisting of neoplastic or non-neoplastic disease, cardiovascular or cerebrovascular disease, renal disease, autoimmune disease, neurological or neurogenerative disease, endocrine disease, and diabetes.
5. A method according to claim 1, wherein said disorder is selected from the group comsisting of breast cancer, colon cancer, pancreatic cancer, lymphoma, prostrate cancer and leukemia.
6. A method according to claim 1, wherein said disorder comprises glomerulonephritis.
7. A method according to claim 1, wherein said disorder comprises periarateris.
8. A method according to claim 1, wherein said disorder is selected from the group consisting of myocardial degeneration, heart disease and stroke.
9. A method according to claim 1, wherein said disorder comprises altherosclorosis.
10. A method according to claim 1, wherein said disorder comprises pituitary adnoma.
11. A method according to claim 1, wherein said disorder comprises type II
diabetes.
diabetes.
12. A method according to claim 1, wherein said disorder comprises sensitivity to toxins.
13. A method according to claim 1, wherein said comparison is conducted using univariat statistics.
14. A method according to claim 1, wherein said comparison is conducted using multivariat statistics.
15. A method according to claim 1, wherein said comparison is conducted using hierarchical cluster analysis.
16. A method according to claim 1, wherein said comparison is conducted using principal component analysis.
17. A method according to claim 1, wherein said comparison is conducted using pattern recognition algorithms to qualitatively and quantitatively identify metabolic profiles and relationships.
18. A method according to claim 1, wherein said biological samples comprise electrochemically active compounds, and including the steps of passing said fluid samples sequentially through a liquid chromatographic column for achieving time-space separation of the materials eluting from the column, and an electrochemical detection apparatus whereby to generate electrochemical patterns of said electrochemically active compounds.
19. A method according to claim 18, including the step of separating said electrochemically active compounds by electrochemical characteristics in said electrochemical detection apparatus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7993598P | 1998-03-30 | 1998-03-30 | |
US60/079,935 | 1998-03-30 | ||
PCT/US1999/006762 WO1999050437A1 (en) | 1998-03-30 | 1999-03-29 | Methodology for predicting and/or diagnosing disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2291889A1 true CA2291889A1 (en) | 1999-10-07 |
Family
ID=22153759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002291889A Abandoned CA2291889A1 (en) | 1998-03-30 | 1999-03-29 | Methodology for predicting and/or diagnosing disease |
Country Status (6)
Country | Link |
---|---|
US (1) | US6558955B1 (en) |
EP (1) | EP0998579A1 (en) |
JP (1) | JP2002511949A (en) |
AU (1) | AU3367799A (en) |
CA (1) | CA2291889A1 (en) |
WO (1) | WO1999050437A1 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030232682A1 (en) * | 1998-02-19 | 2003-12-18 | Rogers William D. | Automatic variable ratio differential |
US7329489B2 (en) * | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
EP1285092A4 (en) * | 2000-04-14 | 2003-07-16 | Metabolon Inc | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
CA2415775A1 (en) * | 2000-07-18 | 2002-01-24 | Correlogic Systems, Inc. | A process for discriminating between biological states based on hidden patterns from biological data |
WO2002025563A1 (en) * | 2000-09-22 | 2002-03-28 | Cryosite Limited | System and method for management of specimens |
US8010295B1 (en) * | 2000-11-06 | 2011-08-30 | IB Security Holders LLC | System and method for selectively classifying a population |
WO2002057989A2 (en) * | 2001-01-18 | 2002-07-25 | Basf Aktiengesellschaft | Method for metabolic profiling |
WO2003017177A2 (en) | 2001-08-13 | 2003-02-27 | Beyong Genomics, Inc. | Method and system for profiling biological systems |
US20070179717A1 (en) * | 2001-09-21 | 2007-08-02 | Milliken Gordon L | System and method for management of specimens |
US20040002842A1 (en) * | 2001-11-21 | 2004-01-01 | Jeffrey Woessner | Methods and systems for analyzing complex biological systems |
US20050013776A1 (en) * | 2003-07-16 | 2005-01-20 | Spindler Stephen R. | Methods of evaluating the dynamics of caloric restriction and identifying caloric restriction mimetics |
US20040180003A1 (en) * | 2003-03-12 | 2004-09-16 | Spindler Stephen R. | Methods of screening for caloric restriction mimetics and reproducing effects of caloric restriction |
US7425700B2 (en) * | 2003-05-22 | 2008-09-16 | Stults John T | Systems and methods for discovery and analysis of markers |
US20040236603A1 (en) * | 2003-05-22 | 2004-11-25 | Biospect, Inc. | System of analyzing complex mixtures of biological and other fluids to identify biological state information |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
AU2004283294B2 (en) * | 2003-10-23 | 2011-03-17 | Kineta Two, Llc | Detection of mutations in a gene associated with resistance to viral infection, OAS1 |
US20050191649A1 (en) * | 2003-10-23 | 2005-09-01 | Illumigen Biosciences, Inc. | Detection of mutations in a gene associated with resistance to viral infection, OAS1 |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US20050244973A1 (en) * | 2004-04-29 | 2005-11-03 | Predicant Biosciences, Inc. | Biological patterns for diagnosis and treatment of cancer |
UA95446C2 (en) * | 2005-05-04 | 2011-08-10 | Іллюміджен Байосайєнсіз, Інк. | Mutations in oas1 genes |
US20070269824A1 (en) * | 2006-03-02 | 2007-11-22 | Jeffrey Albrecht | Methods and systems for evaluating health risk factors by measurement of DNA damage and DNA repair |
US8849577B2 (en) * | 2006-09-15 | 2014-09-30 | Metabolon, Inc. | Methods of identifying biochemical pathways |
CA2662655A1 (en) * | 2006-09-19 | 2008-03-27 | Metabolon, Inc. | Biomarkers for prostate cancer and methods using the same |
US20080306444A1 (en) | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
EP2227132B1 (en) | 2007-10-09 | 2023-03-08 | DexCom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8268579B2 (en) | 2008-01-24 | 2012-09-18 | Pilots Point Llc | Method and medium for detecting the presence or absence of pathogenic staphylococci in a first generation test sample |
US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
AU2014290745A1 (en) | 2013-07-19 | 2015-12-17 | Dexcom, Inc. | Time averaged basal rate optimizer |
CA2945165A1 (en) | 2014-04-08 | 2015-10-15 | Metabolon, Inc. | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment |
CN106153921B (en) * | 2016-08-04 | 2018-09-14 | 北京市神经外科研究所 | Purposes of the biomarker detection reagent in the kit for preparing detection Invasiveness of Pituitary Adenomas |
AU2018354120A1 (en) | 2017-10-24 | 2020-04-23 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11041847B1 (en) | 2019-01-25 | 2021-06-22 | Ixcela, Inc. | Detection and modification of gut microbial population |
CN114651058B (en) | 2019-08-05 | 2023-07-28 | 禧尔公司 | Systems and methods for sample preparation, data generation, and protein crown analysis |
CN114354808A (en) * | 2022-01-06 | 2022-04-15 | 南京大学 | Method for high-flux identification of trace organic pollutants in blood based on trace samples |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3855099A (en) | 1971-08-02 | 1974-12-17 | Environmental Sciences Ass Inc | Electrode for anodic stripping voltammetry |
US4263268A (en) | 1978-11-21 | 1981-04-21 | Shandon Southern Products Limited | Preparation of porous carbon |
US4552013A (en) | 1980-01-14 | 1985-11-12 | Esa, Inc. | Electrochemical system |
US4863873A (en) * | 1980-01-14 | 1989-09-05 | Esa, Inc. | Method for biological testing and/or developing pharmaceuticals for treatment of disorders |
US4404065A (en) | 1980-01-14 | 1983-09-13 | Enviromental Sciences Associates, Inc. | Electrochemical detection system and method of analysis |
US4413505A (en) | 1981-03-09 | 1983-11-08 | Environmental Sciences Associates, Inc. | Electrochemical flow cell, particularly use with liquid chromatography |
GB2078128B (en) | 1980-06-24 | 1984-09-12 | Nat Res Dev | Monitoring gases |
US4500432A (en) | 1981-07-13 | 1985-02-19 | Hewlett-Packard Company | Automated sample concentrator for trace components |
US4976994A (en) | 1985-11-13 | 1990-12-11 | Esa, Inc. | Method for modifying diffusion selectivity of porous fritted carbonaceous electrode |
DE3686030T2 (en) | 1985-11-13 | 1993-03-04 | Esa Inc | ELECTROCHEMICAL TEST SYSTEM. |
US5252333A (en) | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
FR2620620B1 (en) | 1987-09-22 | 1991-04-05 | Atlantic Pharma Prod | INHIBITOR OR DESTRUCTIVE SUBSTANCE OF AT LEAST ONE SINGLE-CELL LIVING BEING CONTAINING FLUORINE F- AND LITHIUM LI + |
US4812344A (en) | 1988-03-28 | 1989-03-14 | Spectran Corporation | Composite capillary tube structure and method of forming |
GB8824780D0 (en) | 1988-10-21 | 1988-11-30 | Unilever Plc | Method of preparation of porous carbon material & material produced by method |
DE3837614A1 (en) | 1988-11-05 | 1990-05-10 | Merck Patent Gmbh | ADSORPTION AGENT FOR CHROMATOGRAPHY |
US5011608A (en) | 1988-11-18 | 1991-04-30 | Dragana Damjanovic | Biogenic amine assay using HPLC-ECD |
US5032240A (en) | 1989-03-27 | 1991-07-16 | Technochem Company | Method of activation of porous carbonaceous electrodes |
US5358802A (en) | 1993-04-01 | 1994-10-25 | Regents Of The University Of California | Doping of carbon foams for use in energy storage devices |
-
1999
- 1999-03-29 AU AU33677/99A patent/AU3367799A/en not_active Abandoned
- 1999-03-29 JP JP54960699A patent/JP2002511949A/en active Pending
- 1999-03-29 CA CA002291889A patent/CA2291889A1/en not_active Abandoned
- 1999-03-29 EP EP99915073A patent/EP0998579A1/en not_active Withdrawn
- 1999-03-29 US US09/424,805 patent/US6558955B1/en not_active Expired - Fee Related
- 1999-03-29 WO PCT/US1999/006762 patent/WO1999050437A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1999050437A1 (en) | 1999-10-07 |
AU3367799A (en) | 1999-10-18 |
US6558955B1 (en) | 2003-05-06 |
JP2002511949A (en) | 2002-04-16 |
EP0998579A1 (en) | 2000-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2291889A1 (en) | Methodology for predicting and/or diagnosing disease | |
CN101023349B (en) | Biomarker for ovarian cancer | |
KR101107765B1 (en) | Use of biomarkers for detecting ovarian cancer | |
US4863873A (en) | Method for biological testing and/or developing pharmaceuticals for treatment of disorders | |
Zhang et al. | Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient | |
JP4864875B2 (en) | Use of plasma proteomic patterns for diagnosis, classification, prediction of response to treatment and clinical behavior in hematological malignancies, stratification of treatment, and disease monitoring | |
Kiernan et al. | Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay | |
US5104639A (en) | Method for biological testing and/or developing pharmaceuticals for treatment of disorders using electrochromatography | |
AU2006336091A1 (en) | Method and markers for the diagnosis of renal diseases | |
CN111983049A (en) | Method for simultaneously detecting trace residues of 14 drug substances in environmental water body | |
EP0972195B1 (en) | Detection of low level analytes in samples | |
Ramos et al. | Automated lab-on-valve sequential injection ELISA for determination of carbamazepine | |
Liu et al. | Lab-on-a-chip electrical multiplexing techniques for cellular and molecular biomarker detection | |
TWI254647B (en) | Method of separating compound(s) from mixture(s) | |
JPH08501638A (en) | Sample preparation method for urinary protein analysis by capillary electrophoresis | |
CN112599239B (en) | Metabolite marker and application thereof in cerebral infarction diagnosis | |
Fitzgerald et al. | Sensor arrays from spectroscopically-encoded polymers: towards an affordable diagnostic device for biomolecules | |
EP0201591B1 (en) | Method for developing pharmaceuticals for treatment of disorders | |
WO2020264513A1 (en) | Compositions and methods for blood and anemia detection | |
Lokhande et al. | Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk | |
CN112611814B (en) | Method for determining 1, 5-anhydroglucitol in dried blood slices | |
CN112305119B (en) | Biomarker for atherosclerotic cerebral infarction and application thereof | |
Yu et al. | Ion chromatographic determination of calcium and magnesium cations in human saliva and urine with a piezoelectric detector | |
US20080293587A1 (en) | Method of Screening a Biological Target for Weak Interactions Using Weak Affinity Chromatography | |
CN1534291A (en) | New type automatic malignent fumour auxiliary diagnostic instrument |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |